Exploring the link between HDL types and heart disease outcomes
Relationship Between High Density Lipoprotein Subtypes and Prognosis in Coronary Heart Disease Patients.
This study is trying to see how different types of good cholesterol (HDL) affect heart disease outcomes in people with coronary artery disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 5000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Beijing Tsinghua Chang Gung Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT06190834 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the relationship between different subtypes of high-density lipoprotein (HDL) and the prognosis of coronary heart disease (CHD). It aims to clarify the complexities surrounding HDL's role in cardiovascular health, particularly in light of conflicting evidence regarding its protective effects. By analyzing data from patients with confirmed coronary artery disease, the study seeks to determine whether the quantity or quality of HDL is more significant in influencing CHD outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old with confirmed coronary artery disease.
Not a fit: Patients with severe comorbid conditions or insufficient data on HDL subtypes may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights that lead to more effective strategies for managing coronary heart disease.
How similar studies have performed: While the relationship between HDL and coronary heart disease has been extensively studied, this specific focus on HDL subtypes is relatively novel and may provide new insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. The age of the patients is over 18 years old; 2. Coronary artery disease was confirmed by coronary angiography. Exclusion Criteria: 1. Severe valvular disease, severe myocarditis, severe hepatic and renal insufficiency, thyroid insufficiency, severe infectious or systemic inflammatory diseases, severe blood diseases, malignant tumors. 2. Lack of data on HDL subtypes.
Where this trial is running
Beijing, Beijing Municipality
- Beijing Tsinghua Changgung Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Study coordinator: Yu Geng
- Email: gya02137@btch.edu.cn
- Phone: 010-56119519
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.